相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
已完成
2
40.0%
招募中
3
60.0%
暂无批准数据
- German regulatory authority BfArM has approved an optimized design for Isofol Medical's ongoing phase Ib/II study of arfolitixorin, expanding inclusion criteria from 45% to 90% of colorectal cancer patients. - The phase II portion will now include a control arm for direct comparison with leucovorin, the current leading folate-based medicine, strengthening the trial's robustness. - Study expansion includes additional chemotherapy regimens and will increase from one to 10-15 study centers across multiple European countries to accelerate patient recruitment. - Arfolitixorin is being developed to enhance the efficacy of established cancer treatments for colorectal cancer, the world's third most common cancer with significant unmet medical need.
- TME Pharma successfully negotiated a 12-month extension on €2.06M in loans from lenders, representing 93.2% of its May and August 2025 fundraising debt. - The company now has financial runway extending into Q2 2027, providing crucial time to advance partnership discussions for its lead cancer and eye disease therapies. - Lenders received 30% additional warrants with extended terms until December 2030, potentially generating €678k in additional funding if fully exercised. - CEO Diede van den Ouden emphasized the extension demonstrates investor confidence and will enable management to accelerate value optimization efforts for NOX-A12 and NOX-E36.
- Silexion Therapeutics received formal written Scientific Advice from Germany's BfArM supporting the design of its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer. - The positive regulatory feedback covers clinical design, dosing plans, patient population strategy, and manufacturing considerations for the RNA interference therapy targeting KRAS-driven cancers. - The company plans to complete regulatory submissions in Israel by end of Q4 2025 and in Germany during Q1 2026, with Phase 2/3 trial initiation targeted for the first half of 2026. - SIL204 represents a potential breakthrough for KRAS-mutated cancers, which are driven by the most common oncogenic gene in human cancers.
- Germany faces challenges in integrating psychedelic-assisted therapy (PAT) due to strict regulations and limited access to psychedelic substances. - Economic burdens of PTSD and depression in Germany highlight the urgent need for more effective interventions like PAT, potentially reducing healthcare costs. - The European Medicines Agency (EMA) is evaluating psychedelics, prompting Germany to prepare for innovative treatments through structured frameworks. - A proposed German training model, BuNT, aims to certify PAT practitioners, addressing the current mismatch between trained therapists and patient demand.
• The 7th Annual Outsourcing in Clinical Trials DACH 2024 conference will convene in Zurich this October, featuring key discussions on European ICH GCP V3 regulations and emerging technologies in clinical trials. • Industry leaders from Bristol Myers Squibb, Novartis, and other major companies will address critical challenges in clinical trial conduct, including AI integration and regional trial revitalization strategies. • The conference will highlight WHO's new guidance on clinical trial diversity and inclusion, with special focus on improving representation of underserved populations in medical research.
- German regulatory authorities have approved Thermosome's Phase 1 trial for THE001, a novel thermosensitive liposomal formulation of doxorubicin, with patient enrollment expected to begin in Q2 2023. - THE001 utilizes a proprietary technology that enables targeted drug release triggered by mild heat, potentially creating up to 15-fold higher local drug concentrations at tumor sites compared to conventional treatments. - The trial will evaluate safety, tolerability, and anti-tumor activity in patients with locally advanced or metastatic soft tissue sarcoma, addressing a significant unmet need in an indication with current response rates below 30%.
